Aggressive Lymphomas
Conference Coverage
FLYER: Four cycles of R-CHOP as good as six in low-risk DLBCL
SAN DIEGO – Survival outcomes were nearly identical and adverse events were lower with four versus six cycles of R-CHOP in patients with favorable...
Video
FLYER: R-CHOP 4 safer, as effective for low-risk DLBCL patients under 60
SAN DIEGO – Progression-free, event-free, and overall survival were comparable with that of patients assigned to six cycles of therapy.
Guidelines
CNS lymphoma guidelines stress patient fitness, not age, in choosing treatment
Patients should be diagnosed fast, treated as aggressively as organ health permits, and in clinical trials if possible.
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
FDA approves biosimilar rituximab for NHL
The U.S.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
News
ASH expands late-breaking abstract session
An additional presentation has been added to the late-breaking abstract session of the 2018 ASH Annual Meeting. The session was expanded from six...
News
CAR T-cell studies to be presented at ASH
Several studies set to be presented at the 2018 ASH Annual Meeting provide new insights regarding chimeric antigen receptor (CAR) T-cell therapies...
Conference Coverage
ASH 2018 coming attractions look at the big picture
Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.
News
Biosimilar deemed equivalent to rituximab in FL
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL)....
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...